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Abstract
Background: Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease of the spine causing pain, stiffness,
loss in physical function, and fatigue. Therefore, the physical and psychological burden of having this chronic
disease can reduce the quality of life. We aimed to explore the relationship between demographic- and disease-
related variables and health-related quality of life (HRQoL) in patients with ax-SpA.
Methods: Demographic- and disease-related, HRQoL-related and treatment data were collected. Disease measures
included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the BAS Functional Index (BASFI), the
BAS Global (BAS-G) score, the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), the Health Assessment
Questionnaire (HAQ) and co-morbidity. HRQoL was assessed using the SF-36 and the utility measures SF-6D and
15D. Variables associated with HRQoL were identified in unadjusted and adjusted analyses.
Results: We examined 380 patients with ax-SpA (67% men) with a mean age of 46 years. Among them, 86%
reported exercising >1 h per week. Mean values were as follows: BASDAI, 3.17; MASES, 3.19; BASFI, 2.71; BAS-G. 3.88;
and HAQ,
0.56. The percentage of current users of NSAIDs was 44%, and of DMARDs 23%. In multivariate analyses, exercising
1–3 h per week (B = 2.73, p = 0.022) and exercising >3 h per week (B = 2.71, p = 0.020), lower HAQ scores (B = −4.
61, p = 0.001), lower BASFI scores (B = −1.05, p = 0.010) and lower BAS-G scores (B = −0.91, p = 0.001) were
independently associated with higher SF-36-PCS scores, whereas modest alcohol consumption (B = 4.63, p = 0.018)
and a lower BAS-G score (B = −1.73, p < 0.001) were independently associated with higher SF-36-MCS scores.
Exercising 1–3 h per week (B = 0.032, p = 0.004) and exercising >3 h per week (B = 0.036, p = 0.001), lower HAQ
scores (B = −0.051, p < 0.001), lower BAS-G scores (B = −0.010, p < 0.001) and co-morbidity (B = −0.014, p = 0.004)
were independently associated with higher 15D scores. Finally, exercising 1–3 h per week (B = 0.045, p = 0.001) and
exercising > 3 h per week
(B = 0.053, p < 0.001), lower HAQ scores (B = −0.054, p = 0.001) and lower BAS-G scores (B = −0.020, p < 0.001)
were associated with higher SF-6D scores.
Conclusions: In patients with ax-SpA, a low level of physical activity, impaired physical function and impaired
general well-being were independently and consistently associated with a decreased HRQoL across all applied
measures.
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Background
Axial spondyloarthritis (Ax-SpA) is a chronic, systemic
inflammatory rheumatic disease affecting the axial skel-
eton. Its inflammatory disease processes can also involve
peripheral joints, entheses and internal organs [1, 2].
Most frequently, the disorder presents with an insidious
onset of back pain in early adulthood, and typically causes
fatigue, stiffness and loss in physical function [2, 3]. The
psychological burden of having such a chronic disease in
addition to the somatic symptoms can have a major
impact on the health-related quality of life (HRQoL) in
patients with ax-SpA, both for patients with ankylosing
spondylitis (AS) and non-radiographically determined ax-
SpA, even at a young age [4–7]. HRQoL is a subjective
and multidimensional concept and can be defined as an
individual’s experience of their general health state, such
as physical, social and mental well-being [8].
Data from the literature indicate no differences in
HRQoL between patients with AS and non-radiographically
determined ax-SpA [9]. Furthermore, patients with ax-
SpA have reported HRQoL scores that are similar to other
inflammatory diseases such as psoriasis and inflammatory
bowel disease [10, 11]. However, patients with ax-SpA re-
port lower HRQoL than do healthy controls [3, 12], and
women with the disease report a lower HRQoL than do
men [2, 13, 14]. Decreased HRQoL in patients with ax-
SpA is associated with fatigue [15], increased disease
activity, decreased daily activity and exercise [16–18], pain,
and adverse psychological factors such as body image dis-
turbance, anxiety and depression [6, 19].
HRQoL measurements can be used for economic
evaluation (cost–utility analysis), and several generic
utility instruments (e.g., 15D, SF-6D and EQ5D) [20, 21]
have been developed. The utility measures can also be used
to calculate quality-adjusted life years (QALYs) [20, 21].
Furthermore, HRQoL can be assessed using other generic
HRQoL measures such as the well-known SF-36 [22, 23].
There is sparse knowledge on the associations between
demographic- and disease-related variables and HRQoL
using utility measures in patients with ax-SpA, especially
after the introduction of new and more targeted medica-
tions [24]. Therefore, the aim of this study was to
explore the relationships between demographic- and
disease-related variables and HRQoL in patients with
ax-SpA, using the utility measures 15D and SF-6D and
the generic HRQoL measure SF-36.
Methods
Patient recruitment
Patients with ax-SpA included in this study were re-
cruited consecutively from two outpatient rheumatology
clinics, one located in the eastern part of Norway
(Martina Hansens Hospital, MHH) and the other in the
southern part (Sorlandet Hospital, SSHF), which also
have been described previously [25]. The patients had to
be 18 years or older and needed to meet the Assessment
of Spondyloarthritis International Society (ASAS) cri-
teria for ax-SpA [26].
Data collection
A broad spectrum of demographic, disease- and
treatment-related data was collected using physical ex-
aminations, laboratory tests, interviews and question-
naires [25]. Demographic data included age, gender,
education level, work status, physical exercise, body
mass index (BMI), smoking and alcohol consumption.
Disease duration was defined as the time between the
date fulfilling the ASAS criteria for ax-SpA and the date
for inclusion in the study, and human leucocyte antigen
(HLA)-B27 status was registered. Disease activity was
assessed using the Bath Ankylosing Spondylitis Activity
Index (BASDAI), the Maastricht Ankylosing Spondylitis
Enthesitis Score (MASES) and C-reactive protein (CRP)
level. Physical function was assessed by the Bath Ankylosing
Spondylitis Functional Index (BASFI) and the Health
Assessment Questionnaire (HAQ) [27]. Data on the Bath
Ankylosing Spondylitis Patient Global Score (BAS-G) and
morning stiffness were also collected. Any additional
current medications including the use of non-steroidal
anti-inflammatory drugs (NSAIDs), synthetic disease-
modifying anti-rheumatic drugs (DMARDs), biological
DMARDs and prednisolone were also recorded. Data on
co-morbidities (yes/no) (heart diseases, pulmonary dis-
eases; neurological, endocrine, haematological, gastro-
intestinal, urogenital, other rheumatology diseases, mental
disorders and cancers) were collected, and we computed a
summed score to reflect co-morbidity. This score has also
been used in other studies [25, 28, 29].
HRQoL was assessed using both the SF-36 and 15D
tools, which also has been described previously [30]. The
former is a self-reported and generic questionnaire,
including eight domains: general health, bodily pain, phys-
ical function, role limitations (physical), mental health,
vitality, social function and role limitations (emotional).
The eight domains can be combined into a physical and
mental sum scale that reflects physical and mental health.
The physical component summary (PCS) and the mental
component summary (MCS) scales were also used in this
study. Regression analyses were performed to impute
missing values in accordance with the instruction by the
developer of the questionnaire [22, 23]. The SF-36 scales
were scored according to published scoring procedures,
and each scale was expressed using values from 0 to 100,
with 100 representing excellent health [22, 23, 31, 32].
From the SF-36 score we also generated the utility
measure SF-6D [21]. This is based on 11 questions from
the SF-36 and includes six dimensions, each with four to
six levels. The SF-6D utility scores range from 0.29 to
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1.00, with 1.00 indicating “full health”. The Norwegian
standard SF-36 version 1.00 was used to derive the SF-6D.
Regression analyses were performed to impute missing
values in accordance with instructions published by the
developer of the questionnaire [21, 22]. The SF-6D ques-
tionnaire has been validated for its psychometric proper-
ties in other studies in several countries [21].
The 15D questionnaire is a generic, multidimensional,
standardized evaluation tool of HRQoL that can be used
primarily as a single index measure, but also as a profile
utility measure, which has been described previously
[28]. It describes the patient’s health status, assessing 15
dimensions: mobility, vision, hearing, breathing, sleep-
ing, eating, speech, elimination, usual activities, mental
function, discomfort and symptoms, depression, distress,
vitality and sexual activity [20]. Each dimension com-
prises one question with five response categories. A
single utility index score is obtained by incorporating
population-based preference weights to the dimensions
[33, 34]. The utility scores fall between 0.0 (being dead)
and 1.00 (no problems on any dimension). Regression
analyses were performed to impute missing values in ac-
cordance with the guidelines published by the developer
of the questionnaire [20]. The questionnaire has been
validated thoroughly for psychometric properties in
other studies in several countries [20, 33, 34].
Statistical analyses
Statistical analyses were performed using IBM SPSS
Statistics (IBM Corp., Armonk, NY, USA (version 22)).
Continuous variables are presented as the mean and
standard deviation (SD, in parentheses) and categorical
variables as numbers and proportions (%). Chi-squared
tests and Student’s t tests were used to compare
differences between subgroups. To further examine the
differences in SF-36 scores between our patients and
norm-based scores, we calculated the effect size, calcu-
lated by subtracting the mean SF-36 scores in the pa-
tients from the mean SF-36 scores in the general
population and then dividing by the SD for the general
population [35]. We applied Cohen’s standards for effect
size values as: small effect 0.2; medium effect 0.5; and
large effect 0.8 [36].
Multiple linear regression analysis (general linear
model (GLM) in SPSS) was used to examine the
adjusted association between demographic- and disease-
related variables and HRQoL (SF-36-PCS, SF-36-MCS,
15D and SF-6D scores). The independent variables in
the multiple analyses were chosen based on univariate
associations with HRQoL, clinical experience and factors
associated with HRQoL in previous studies [6, 15, 37].
In the final multivariate model, we included the demo-
graphic variables, disease activity (assessed by BASDAI
and MASES scores), health status (assessed by HAQ,
BASFI and BAS-G scores), damage (assessed by BASMI
score), co-morbidity and treatment centre as independ-
ent variables. Treatment, disease duration and morning
stiffness were also tested in the models as independent
variables; however, the same patterns persisted when ex-
ploring these associations with HRQoL as dependent
variables, so were excluded. The final tested variables are
listed in Table 3. For robustness, we also tested the
models by backward multiple regression analyses. The
level of significance was set at p < 0.05.
Ethical and legal aspects
The study was approved by the Regional Committee for
Medical Research Ethics (REK # 4.2007.2152).
Results
Demographic- and disease-related characteristics
In total, 389 patients with ax-SpA were included in the
study. Among these, 380 gave valid responses to the
main HRQoL measure SF-36, and comprised the final
sample. The only significant difference between the non-
responders (n = 9) and responders to SF-36 was age
(57.7 (SD 7.1) vs. 45.5 (12.0) years (p = 0.001).
When comparing demographic variables listed in
Table 1 between the two centres, MHH (n = 252) and
SSHF (n = 128), a statistically significant difference was
identified for duration of education >13 years (60% vs.
49%; p = 0.038). Concerning disease-related variables,
patients from MHH had better outcomes compared with
SSHF in terms of BASDAI (2.9 (2.1) vs. 3.7 (2.1),
p = 0.001); BASFI (2.5 (2.2) vs. 3.0 (2.3), p = 0.045);
BAS-G (3.6 (2.5) vs. 4.4 (2.6), p = 0.009); and MASES
(2.4 (2.90) vs. 4.90 (4.66), p < 0.001). Patients from
MHH currently used more biological DMARD treat-
ment than those from SSHF (30% vs. 9%, p < 0.001). For
the remaining variables in Table 1, there were no signifi-
cant differences between the centres. For the analysis,
we pooled the patient data and adjusted for the two cen-
tres in multivariate analyses.
The mean age for the 380 patients was 45.8 (12.0) years;
67% were men; 75% were married or cohabiting; 51% re-
ported exercising >3 h per week and 35% 1–3 h per week.
Mean outcome values were as follows: BASDAI 3.17 (2.11);
MASES 3.19 (3.75); BASFI 2.71 (2.23); BAS-G 3.88 (2.57);
and HAQ 0.56 (0.49). Current users of NSAIDs comprised
44% of the sample versus 23% for biological DMARDs,
and 90% were HLA-B27 positive. When comparing
women and men with ax-SpA (Table 1), women had a
lower BMI (25.5 (4.7) vs. 27.5 (4.5) kg/m2; p < 0.001) and
lower alcohol consumption (1–6 glasses per week (67% vs.
71%), more than 7 glasses per week (7% vs. 13%)
p = 0.012). Women reported higher MASES (4.42 (3.85)
vs. 2.57 (3.53), p < 0.001), lower BASMI (2.03 (1.60) vs.
2.38 (2.19), p = 0.013) and higher HAQ scores (0.64 (0.53)
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Table 1 Demographic factors, co-morbidity, disease markers, disease activity measures, damage and health status in an axial
spondyloarthritis outpatient clinic
Total (n = 380)
All Women (n = 127) 33% Men (n = 253) 67% p
Demographic factors
Age (years) 45.8 (12.0) 45.8 (12.4) 45.4 (11.8) 0.754
Married/cohabiting 286 (75%) 94 (74%) 192 (76%) 0.642
Employed 263 (73%) 81 (67%) 185 (74%) 0.088
Education 0.736
≤ 10 years 42 (12%) 13 (10%) 30 (12%)
11–13 years 122 (32%) 39 (31%) 83 (33%)
> 13 years 213 (56%) 75 (59%) 138 (55%)
Exercise <1 h per week 54 (14%) 16 (13%) 38 (15%) 0.523
Exercise 1–3 h per week 132 (35%) 47 (37%) 85 (34%)
Exercise >3 h per week 191 (51%) 63 (50%) 128 (51%)
Current smoker 105 (28%) 36 (28%) 69 (28%) 0.861
Alcohol consumption (per week) 0.023
Never 73 (19%) 33 (26%) 40 (16%)
1–6 glasses 263 (70%) 84 (67%) 179 (71%)
7 glasses or more 41 (11%) 9 (7%) 33 (13%)
BMI (kg/m2) 26.9 (4.6) 25.5 (4.7) 27.5 (4.5) <0.001
Disease duration (years) 13.8 (11.4) 12.6 (11.2) 14.4 (11.5) 0.158
Disease marker
HLA-B27 positive 331 (90%) 107 (87%) 224 (91%) 0.182
Disease activity measures
CRP (mg/dl) 8.58 (11.94) 7.89 (13.25) 8.2 (11.24) 0.446
BASDAI (0–10) 3.17 (2.11) 3.46 (2.06) 3.03 (2.12) 0.059
MASES (0–13) 3.19 (3.75) 4.41 (3.85) 2.57 (3.54) <0.001
Health status
Morning stiffness 0.663
< 30 min 230 (60%) 76 (62%) 148 (59%)
> 31 min 151(40%) 47 (38%) 101 (41%)
BASFI (0–10) 2.71 (2.23) 2.77 (2.24) 2.68 (2.22) 0.740
BAS-G (0–10) 3.88 (2.57) 4.03 (2.51) 3.81 (2.61) 0.447
HAQ (0–3) 0.56 (0.49) 0.64 (0.53) 0.52 (0.47) 0.034
Damage score
BASMI (0–10) 2.39 (2.41) 2.03 (1.60) 2.38 (2.19) 0.013
Current treatment
NSAIDs 167 (44%) 59 (47%) 108 (43%) 0.485
Synthetic DMARDs 19 (5%) 8 (6%) 11 (4%) 0.410
Biological DMARDs 88 (23%) 23 (18%) 65 (25%) 0.098
Prednisolone 17 (4%) 7 (5%) 10 (4%) 0.535
Co-morbidity
Mean total score for co-morbidity (range 0–10) 0.7 (0.9) 0.7 (0.9) 0.6 (0.9) 0.542
Continuous variables are presented as the mean and standard deviation (SD) and categorical variables as number and percentage (%). Bold p values
indicate significant differences
Key: BMI body mass index, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index,
MASES Maastricht Ankylosing Spondylitis Enthesitis Score, BASFI Bath Ankylosing Spondylitis Functional Index, BAS-G Bath Ankylosing Spondylitis Patient
Global Score, HAQ Health Assessment Questionnaire, BASMI Bath Ankylosing Spondylitis Metric Index, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs
disease-modifying anti-rheumatic drugs
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vs. 0.52 (0.47), p = 0.034). For the other variables listed in
Table 1, no statistically significant differences were found
between men and women.
HRQoL in patients with ax-SpA
When comparing HRQoL between the MHH and SSHF
centres, patients from MHH reported higher scores for
the SF-36 domains: vitality (49.5 (20.2) vs. 44.3 (20.0),
p = 0.019); bodily pain (51.0 (20.0) vs. 43.6 (20.9),
p = 0.001), physical role limitations (46.7 (41.8) vs. 34.9
(35.5), p = 0.014); SF-36-PCS (40.6 (9.1) vs. 37.7 (10.0),
p = 0.006); and SF-6D (0.67 (0.10) vs. 0.64 (0.10),
p = 0.003).
When comparing HRQoL between women and men
(Table 2), women reported significantly lower scores for
the SF-36 domains of bodily pain (45.3 (19.8) vs. 50.1
(20.5), p = 0.025) and physical role limitations (36.5 (39.8)
vs. 46.5 (41.7), p = 0.024). However, when comparing the
SF-36 scores in patients with ax-SpA and published
norm-based SF-36 reference data for the general popula-
tion [35], the patients reported significantly lower scores
(p < 0.001) for all eight SF-36 dimensions. The differences
in effect size for the SF-36 dimensions were as follows:
mental health −0.20; vitality −0.63; bodily pain −0.90;
general health −0.98; social function −0.49; physical func-
tion −0.63; physical role −0.89; and emotional role −0.38.
Adjusted associations between demographic- and
disease-related variables and HRQoL
In the multivariate analyses (Table 3), exercising 1–3 h
per week (B = 2.73, p = 0.022) and exercising >3 h per
week (B = 2.71, p = 0.020), lower HAQ scores
(B = −4.61, p = 0.001), lower BASFI scores (B = −1.05,
p = 0.010) and lower BAS-G scores (B = −0.91,
p = 0.001) were independently associated with higher SF-
36-PCS values. Modest alcohol consumption (B = 4.63,
p = 0.019) and lower BAS-G scores (B = −1.73, p < 0.001)
were independently associated with higher SF-36-MCS.
Exercising 1–3 h per week (B = 0.032, p = 0.004) and exer-
cising >3 h per week (B = 0.036, p = 0.001), lower HAQ
scores (B = −0.051, p < 0.001), lower BAS-G scores
(B = −0.010, p < 0.001) and co-morbidity (B = −0.014,
p = 0.004) were independently associated with a higher
15D score. Finally, exercising 1–3 h per week (B = 0.045,
p = 0.001) and exercising >3 h per week (B = 0.053,
p < 0.001), lower HAQ scores (B = −0.054, p = 0.001) and
lower BAS-G scores (B = −0.020, p < 0.001) were associ-
ated with higher SF-6D scores. The demographic- and
disease-related variables included in the multiple analyses
explained 57.1% of the variance in SF-36-PCS, 21.5% in
SF-26-MCS, 60.2% in the 15D scores and 56.9% in
the SF-6D scores. The same results were seen when the
multivariate model was run backwards (data not shown).
Discussion
When exploring the associations between demographic-
and disease-related variables and HRQoL in patients
with ax-SpA, our main finding was that low levels of
exercise, impaired physical function (HAQ scores) and
impaired general disease-associated well-being (BAS-G
scores) were consistently and independently associated
with decreased HRQoL across different relevant mea-
sures. Interestingly, in the adjusted analysis, apart from
exercise intensity, no significant associations were found
between demographic variables and the HRQoL mea-
sures SF-36-PCS, SF-36-MCS, 15D and SF-6D.
Our patients with ax-SpA reported lower HRQoL
(SF-36 scores) compared with norm-based SF-36 refer-
ence scores in Norway [35], with the effect size ranging
from −0.20 (mental health) to −0.98 (general health). The
effect sizes indicate a substantial burden on HRQoL in the
patient group, especially within the physical SF-36
domains. Our patients’ SF-36 scores were similar to the
scores of Alkan et al. (2013) [15] who assessed HRQoL in
Turkish patients with ax-SpA, highlighting the burden of
this disease for such patients.
Minor statistically significant differences between
female and male patients were only found for some
Table 2 Health-related quality of life assessed by SF-36,
SF-6D and 15D scores in outpatient clinic patients with
axial spondyloarthritis, for all subjects, and for women and
men separately
All Women
n = 127
Men
n = 253
p
Health-related quality of life
SF-36a
Mental health 77.2 (14.6) 77.1 (14.1) 77.2 (14.8) 0.952
Vitality 47.9 (20.3) 44.9 (29.9) 49.2 (19.8) 0.056
Bodily pain 48.5 (20.4) 45.2 (19.8) 50.1 (20.5) 0.025
General health 53.8 (21.1) 55.3 (21.3) 53.0 (21.0) 0.336
Social function 75.8 (22.1) 73.9 (22.5) 75.8 (21.8) 0.239
Physical function 73.5 (20.2) 72.4 (19.1) 74.0 (20.8) 0.455
Physical role limitations 43.3 (41.3) 36.5 (39.8) 46.5 (41.7) 0.024
Emotional role limitations 72.3 (39.9) 69.7 (42.1) 73.6 (38.7) 0.375
SF-36-PCS 39.6 (9.5) 38.7 (9.2) 40.1 (9.6) 0.169
SF-36-MCS 48.3 (10.2) 47.7 (10.3) 48.5 (10.2) 0.498
SF-6Db 0.66 (0.10) 0.66 (0.10) 0.67 (0.08) 0.395
15Dc 0.85 (0.09) 0.85 (0.08) 0.85 (0.10) 0.859
Data are shown as the mean and (SD)
Key: SF-36-PCS physical component summary, SF-36-MCS mental component
summary. Continuous variables are expressed as the mean and standard
deviation (SD). Independent-sample Student’s t tests were used for group com-
parisons. Bold p values indicate significant differences
aThe SF-36 range is 0–100, where 100 indicates a high HRQoL
bThe SF-6D range is 0–1, where 1 indicates a high HRQoL
cThe 15D range is 0–1, where 1 indicates a high HRQoL
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demographic factors (BMI and alcohol consumption),
some disease-related variables (swollen joints, entheses
score, physical function and skeletal damage score) and
some HRQoL domains (SF-36 bodily pain and physical
role limitations; Tables 1 and 2). This suggests that the
overall burden and the perception of ax-SpA are similar
rather than different between genders. In previous stud-
ies, women with ax-SpA reported lower HRQoL values
than men [13, 14], as well as more pain and more phys-
ical consequences of pain [13, 14]. Our data are consist-
ent with those reports as our female patients with ax-
SpA reported more bodily pain and reported reduced
physical role limitations on the HRQoL measure SF-36.
In patients with ax-SpA, pharmacological anti-
inflammatory treatment with NSAIDs and anti-tumour
necrosis factor (TNF)-α treatment have been shown to
improve physical function and quality of life [38, 39].
The percentage of ax-SpA patients in our study on
NSAIDS was 44%, and users of biological DMARDs
comprised 23%. This may explain the rather low level of
disease activity seen in several measures reflecting this
(e.g., BASDAI scores) in our study.
Exercise intensity was identified as being significantly
associated with HRQoL across the different measures.
Along with targeted treatment, exercise and rehabilita-
tion therapy are cornerstones in the management of ax-
SpA, including patients with AS [38–41]. Systematic
workouts such as water exercises and exercises for
increasing flexibility, muscle strength and cardio-
respiratory fitness in ordinary clinical care have been
shown to be beneficial [17, 40]. Good physical function
implies coping in terms of daily activities and living,
which further implies that the patients with ax-SpA can
live nearly ordinary lives despite their chronic illness.
Exercise is an important part of the holistic approach in
treatment and care of this patient type [17, 40].
Co-morbidity was only associated with the 15D
measure and not with the other HRQoL measures.
Because the items included in this questionnaire are
more concrete than those included in the other
questionnaires, they may capture the disease-related
limitations caused by ax-SpA more specifically [20–23].
Furthermore, the items addressed in the 15D question-
naires might be considered easier to respond to [20, 22],
which is also our clinical experience [28]. Another ex-
planation for the lack of association between co-
morbidity and HRQoL might be the low number of co-
morbidities in our patients, which seemed to be lower
than in previous studies [24].
Back pain is a characteristic symptom in patients with
ax-SpA [3]. Pain was only measured by the SF-36 as
bodily pain along with physical function measures that
might be affected. When we compared the SF-36 bodily
pain score with norm-based scores, the effect size
revealed a substantial difference between the two groups
[35]. These comparisons underline the pain problem in
patients with ax-SpA, although it is not site specific.
Other HRQoL studies in patients with ax-SpA have also
included a visual analogue scale (VAS) [15, 42], and a
more specific pain measure might have revealed more
nuanced and other findings. On the other hand, the con-
sequence of pain in terms of reduced functioning was
extensively covered by the other patient-reported mea-
sures in our study.
To our knowledge, this is the first study measuring
HRQoL using the utility measures 15D and SF-6D in pa-
tients with ax-SpA. Interestingly, in the multivariate
models shown in Table 3, the two utility measures—easier
to use than the more comprehensive SF-36—performed as
well as the SF-36-PCS expressed as the variance (R2) and
compared better with the SF-36-MCS outcome. This might
be interpreted as a test of concurrent validity for the two
utility measures [43]. Furthermore, the relatively high vari-
ances in HRQoL (except for SF-36-MCS) explained by the
demographic- and disease-related variables included in the
multiple/adjusted comparisons might also indicate that the
independent variables chosen for the analyses (those that
are mostly collected in ordinary clinical care) were suitable
[37, 43]. On the other hand, there is a question as to
whether there were too many independent/explanation
variables in the multiple analyses or whether there were
overlaps between the questions included in the measures
in the independent and dependent variables in the multiple
regression model, such as the HAQ and SF-36-PCS mea-
sures [22, 23, 44]. The high validity of the utility measures,
compared with SF-36 as the gold standard for the assess-
ment of HRQoL, could be of importance, as only feasible
HRQoL measures might have the potential to be used as
part of the clinical standard in routine clinical care.
The disease-related independent variables that
remained as significant associations with HRQoL in the
adjusted analyses were all self-reported health or symp-
tom measures. In their conceptual model, Wilson and
Cleary linked clinical variables with HRQoL [45]. Their
model shows how measures can be thought of as exist-
ing on a continuum of increasing biological (e.g., object-
ive ax-SpA disease measures), social and psychological
complexity. In this model, HRQoL is influenced by self-
reported symptoms of functional status, along with
characteristics of the individual and the environment,
and not biological and other objective health and disease
measures [45]. This seems to have been the case in our
study as well.
Methodological considerations
The strengths of this study were that all the participants
were recruited consecutively from two geographically re-
stricted areas and the numbers were sufficient for robust
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analyses. Further, apart from age, there were few exclusion
criteria and there were no differences between the patients
included in the study and those who did not want to par-
ticipate. At the time the data were collected, patients at
MHH used significantly more biological DMARDS than
did those at SSHF, which might explain some of the
differences in self-reported health status. However, in the
adjusted analyses, the centres did not turn out to be sig-
nificantly associated with dependent variables. Therefore,
pooling of the patients from the two areas was justified, as
there were only small differences between them. Another
strength of our study is that we used several validated
patient-reported questionnaires and outcomes to cover
the patients’ perspectives [20–22, 27].
A major limitation of our study was the cross-
sectional study design, which does not permit any causal
interpretations. In this regard, our results should be
interpreted with caution as we only found associations
between dependent and independent variables. Interest-
ingly, when the adjusted models were run backwards,
the results remained the same, indicating that our find-
ings are likely robust.
Conclusions
In patients with ax-SpA, low physical activity
(exercising <1 h per week), impaired physical function
(higher HAQ scores) and impaired general ax-SpA disease
well-being outcomes (higher BAS-G scores) were inde-
pendently and consistently associated with decreased
HRQoL across several measures. This indicates that the
two utility measures (15D and SF-6D) reflect and capture
HRQoL in patients with ax-SpA to the same extent as the
SF-36. Our study has confirmed that ax-SpA negatively
influences HRQoL and suggests that physical exercise is
important as a specific treatment strategy to maintain and
improve HRQoL in patients with ax-SpA.
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